| EROAD Limited (ERD) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$162 |
Application for quotation of securities - ERD
|
2 Jul 2026 10:20AM |
$0.845 |
$0.860 |
risen by
1.78%
|
|
| Martin Currie Real Income Fund - Active ETF (R3AL) |
Financials |
$461 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.530 |
$1.530 |
fallen by
0%
|
|
| Franklin Global Growth Fund (Managed Fund) (FRGG) |
Financials |
$153 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.640 |
$1.650 |
risen by
0.61%
|
|
| Franklin Australian Absolute Return Bond Fund (Managed Fund) (FRAR) |
Financials |
$696 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.035 |
$1.035 |
fallen by
0%
|
|
| Franklin Global Systematic Equity FD - Active ETF (FGSE) FRANKLIN GLOBAL SYSTEMATIC EQUITY FD - ACTIVE ETF |
Financials |
$273 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$3.600 |
$3.600 |
fallen by
0%
|
|
| Western Asset Enhanced Income Fund - Active ETF (FEIF) WESTERN ASSET ENHANCED INCOME FUND - ACTIVE ETF |
Financials |
$519 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.140 |
$1.140 |
fallen by
0%
|
|
| ClearBridge Global Infrastructure Value Fund Active ETF (CUIV) |
Financials |
$799 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.360 |
$1.360 |
fallen by
0%
|
|
| ClearBridge Global Infrastructure Value Fund (Hedged) Active ETF (CIVH) |
Financials |
$1,015 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.145 |
$1.145 |
fallen by
0%
|
|
| ClearBridge Global Infrastructure Income Fund (Hedged) Active ETF (CIIH) |
Financials |
$1,231 |
Final Distribution Details 30 June 2026
|
2 Jul 2026 10:19AM |
$1.515 |
$1.515 |
fallen by
0%
|
|
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$4 |
Proposed issue of securities - SCP
|
2 Jul 2026 10:18AM |
$0.050 |
$0.050 |
fallen by
0%
|
|
| Nine Entertainment Co. Holdings Limited (NEC) ORDINARY FULLY PAID |
Communication Services |
$1,455 |
Notification of cessation of securities - NEC
|
2 Jul 2026 10:17AM |
$0.900 |
$0.918 |
risen by
1.94%
|
|
| Conrad Asia Energy Ltd (CRD) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$109 |
Application for quotation of securities - CRD
|
2 Jul 2026 10:17AM |
$0.485 |
$0.560 |
risen by
15.46%
|
|
| Nutritional Growth Solutions Ltd (NGS) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
Notice of Annual General Meeting/Proxy Form
|
2 Jul 2026 10:16AM |
$0.022 |
$0.022 |
fallen by
0%
|
|
| Sentinel Metals Limited (SNM) ORDINARY FULLY PAID |
Materials |
$34 |
Acquisition of the Big Springs Gold Project Presentation
|
2 Jul 2026 10:15AM |
$0.620 |
$0.620 |
fallen by
0%
|
|
| Cyclopharm Limited (CYC) ORDINARY FULLY PAID |
Health Care |
$63 |
CYC First-Half 2026 Update
|
2 Jul 2026 10:11AM |
$0.510 |
$0.500 |
fallen by
1.96%
|
|
CYC - Price-sensitive ASX Announcement
Full Release
Key Points
- Record 1H FY26 revenue of $17.1 million, up 11% from 1H FY25.
- US Technegas® revenue grew by 73% year-on-year.
- International guidelines now include US, European, and ANZ markets.
- Delayed US installation targets shifted to post-December 2026.
- Medium-term target of 2,000 US installations remains.
- AI-driven expansion of Technegas® clinical applications.
- Closing cash balance of $12.2 million as of June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$5,038 |
Change of Director's Interest Notice - Dean Banks
|
2 Jul 2026 10:09AM |
$6.035 |
$6.160 |
risen by
2.07%
|
|
| EROAD Limited (ERD) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$162 |
Capital Change Notice - Issue of ordinary shares
|
2 Jul 2026 10:08AM |
$0.840 |
$0.860 |
risen by
2.38%
|
|
| Aland Equity Group Limited (AEG) ORDINARY FULLY PAID |
Financials |
$71 |
Appointment of Chief Operating and Financial Officer
|
2 Jul 2026 10:07AM |
$0.086 |
$0.096 |
risen by
11.63%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$5,674 |
FDA Alignment to Advance ProstACT Global Phase 3 Trial
|
2 Jul 2026 10:07AM |
$17.060 |
$16.720 |
fallen by
1.99%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 trial in the U.S.
- FDA agrees with the clinical protocol and proposed statistical framework for the trial.
- Part 2 of the trial continues to recruit patients internationally where approved.
- The trial aims to redefine the integration of radiopharmaceutical therapy in clinical practice.
- ProstACT Global Phase 3 includes a multicenter trial targeting around 490 patients.
- Telix Pharmaceuticals is a global radiopharmaceutical company focused on cancer theranostics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Halo Technologies Holdings Ltd (HAL) ORDINARY FULLY PAID |
Financials |
$4 |
Proposed issue of securities - HAL
|
2 Jul 2026 10:06AM |
$0.012 |
$0.013 |
risen by
8.33%
|
|
| Peel Mining Limited (PEX) ORDINARY FULLY PAID |
Materials |
$143 |
Removal from Official List
|
2 Jul 2026 10:05AM |
$0.160 |
$0.160 |
fallen by
0%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$758 |
NTA & Top 20 Investments as at 30 June 2026
|
2 Jul 2026 10:04AM |
$2.850 |
$2.890 |
risen by
1.40%
|
|
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$15 |
BDX: BCAL to Acquire Shares in Genetic Signatures
|
2 Jul 2026 10:04AM |
$0.068 |
$0.068 |
fallen by
0%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL to acquire 10.2% of Genetic Signatures.
- Acquisition cost is $1,390,119 for 23,173,644 shares.
- Genetic Signatures specializes in real-time PCR-based diagnostics.
- BCAL aims to leverage Genetic Signatures' market and technology.
- Acquisition complements BCAL's cancer detection focus.
- Genetic Signatures has FDA clearance for its products.
- Potential growth in diagnostics infrastructure and international markets.
- Enhances BCAL's commercial operations in Asia Pacific, EMEA, and US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$28 |
BCAL to Acquire Shares in Genetic Signatures
|
2 Jul 2026 10:04AM |
$0.071 |
$0.075 |
risen by
5.63%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL to acquire 23,173,644 shares in Genetic Signatures for $1,390,119.
- The acquisition represents a 10.2% stake in Genetic Signatures Ltd.
- BCAL's product portfolio in early cancer detection is synergistic with Genetic Signatures' infectious disease diagnostics.
- The deal aims to leverage complementary capabilities for future growth.
- Genetic Signatures provides BCAL exposure to broader diagnostics infrastructure and international markets.
- Genetic Signatures has achieved FDA 510(k) clearance for its EasyScreen™ Gastrointestinal Parasite Detection Kit.
- The acquisition supports BCAL's strategy to enhance its diagnostics platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Butn Limited (BTN) ORDINARY FULLY PAID |
Financials |
$6 |
Non-core asset sale of $4.1M and debt facility extension
|
2 Jul 2026 10:03AM |
$0.015 |
$0.017 |
risen by
13.33%
|
|
BTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Butn Limited has executed a binding sale agreement with Working Capital Finance Pty Ltd (WCF) for the sale of its Smash Repair Factoring Business for $4.1 million.
- The transaction includes $2.0 million received at completion, approximately $2.0 million of deferred consideration, and a $100,000 deposit already received.
- The Smash Repair Factoring Business is considered non-core, contributing less than 15% of FY25 Gross Revenue and less than 5% of FY25 Group Assets.
- Butn will provide WCF with a secured funding facility post-completion, enabling continued secured interest income.
- The sale allows Butn to focus on its core strategic priorities and simplifies its operating model.
- The Company has amended its Corporate Credit Facility with an agreed phased repayment schedule, extending the maturity date to 31 August 2026.
- The transaction and debt facility amendment are expected to reduce Butn's cost base by over $1.5 million and contribute towards sustainable profitability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
